These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 19696708)
1. Insulin glargine (Lantus) and cancer risk. Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708 [No Abstract] [Full Text] [Related]
2. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin]. Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234 [No Abstract] [Full Text] [Related]
3. Insulin detemir (levemir), a new long-acting insulin. Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022 [TBL] [Abstract][Full Text] [Related]
5. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850 [TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. McFarland MS; Cripps R Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689 [TBL] [Abstract][Full Text] [Related]
8. Cancer risk in diabetic patients treated with insulin glargine? Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447 [TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU Diabet Med; 2011 Mar; 28(3):276-86. PubMed ID: 21309835 [TBL] [Abstract][Full Text] [Related]
10. [Insulin and cancer: myth or reality?]. Tran C; Gariani K; Philippe J Rev Med Suisse; 2010 Jun; 6(252):1188-90, 1192. PubMed ID: 20614753 [TBL] [Abstract][Full Text] [Related]
11. Insuline glusine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther; 2006 Apr; 48(1233):33-4. PubMed ID: 16625142 [TBL] [Abstract][Full Text] [Related]
12. Where now for insulin glargine--a time for pragmatic medicine? Thomson GA; Craig R Int J Clin Pract; 2009 Oct; 63(10):1413-5. PubMed ID: 19689485 [No Abstract] [Full Text] [Related]
13. Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction. Garg SK Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():1-4. PubMed ID: 18577151 [No Abstract] [Full Text] [Related]
14. Insulin glargine (Lantus), a new long-acting insulin. Med Lett Drugs Ther; 2001 Aug; 43(1110):65-6. PubMed ID: 11490321 [No Abstract] [Full Text] [Related]
15. [Cancer more common in diabetes. Maybe the treatment itself also plays a role]. Nilsson PM; Eliasson B Lakartidningen; 2010 Jan 27-Feb 2; 107(4):170-1. PubMed ID: 20333969 [No Abstract] [Full Text] [Related]
16. Type 2 diabetes: the role of basal insulin therapy. LeRoith D; Levetan CS; Hirsch IB; Riddle MC J Fam Pract; 2004 Mar; 53(3):215-22. PubMed ID: 15000929 [No Abstract] [Full Text] [Related]
17. Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine. Janka HU Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():35-41. PubMed ID: 18577155 [TBL] [Abstract][Full Text] [Related]
18. [Insulin treatment in type 2 diabetes]. Birkeland KI Tidsskr Nor Laegeforen; 2006 Mar; 126(7):919-20. PubMed ID: 16554885 [No Abstract] [Full Text] [Related]
19. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin: response to Barnett et al. Kanna B; Abreu-Pacheco H Diabetes Care; 2007 Feb; 30(2):445-6; author reply 446. PubMed ID: 17259531 [No Abstract] [Full Text] [Related]